High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation

References

• Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192–204
   PubMed Web of Science ®Google Scholar
• Gjertsen H, Weiland O, Oksanen A, Soderdahl G, Broome U, Ericzon BG. Liver transplantation for HCV cirrhosis at Karolinska University Hospital Huddinge, Stockholm. Transplant Proc 2006; 38: 2675–6
   PubMed Web of Science ®Google Scholar
• Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005; 3: 311–8
   PubMedGoogle Scholar
• Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17–35
   PubMed Web of Science ®Google Scholar
• Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852–8
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–65
   PubMed Web of Science ®Google Scholar
• Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067–76
   PubMed Web of Science ®Google Scholar
• Samuel D. Antiviral treatment of recurrent hepatitis C after liver transplantation: the need for a multifaceted approach. Hepatology 2005; 41: 436–8
   PubMedGoogle Scholar
• Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon alpha-2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642–50
   PubMed Web of Science ®Google Scholar
• Burton JR, Jr, Rosen HR. Treatment of HCV recurrence: do the pretransplantation rules apply?. Liver Transpl 2006; 12: 1044–8
   PubMedGoogle Scholar
• Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alpha-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124–9
   PubMed Web of Science ®Google Scholar
• Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2a plus ribavirin. Gastroenterology 2006; 131: 1040–8
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 703–14
   PubMed Web of Science ®Google Scholar
• Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103–7
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 654–9
   PubMed Web of Science ®Google Scholar
• Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebvre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 1999; 37: 1567–9
   PubMed Web of Science ®Google Scholar
• Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 2259–66
   PubMed Web of Science ®Google Scholar
• Yun Z, Lara C, Johansson B, Lorenzana de Rivera I, Sonnerborg A. Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 1996; 49: 155–60
   PubMed Web of Science ®Google Scholar
• Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409–17
   PubMed Web of Science ®Google Scholar
• Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long- term outcome in patients treated with interferon alpha-2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999; 6: 237–42
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alpha-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609–17
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viraemia. J Hepatol 2006; 44: 97–103
   PubMed Web of Science ®Google Scholar
• Dumortier J, Ducos E, Scoazec JY, Chevallier P, Boillot O, Gagnieu MC. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J Viral Hepat 2006; 13: 538–43
   PubMedGoogle Scholar
• Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11: 84–7
   PubMed Web of Science ®Google Scholar
• Berg T, Von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 vs 72 weeks of peginterferon alpha-2a plus ribavirin. Gastroenterology 2006; 130: 1086–97
   PubMed Web of Science ®Google Scholar